Shi-Shuang Cui1, Juan-Juan Du1, Shi-Hua Liu2, Jie Meng3, Yi-Qi Lin1, Gen Li1, Yi-Xi He1, Ping-Chen Zhang1, Shengdi Chen1, Gang Wang1. 1. Department of Neurology & Co-innovation Center of Neuroregeneration, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Department of Neurology, Suzhou Municipal Hospital of Anhui, Suzhou, Anhui, China. 3. Department of Geriatrics, the First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Abstract
OBJECTIVE: Lymphocyte activation gene-3 (LAG-3) could mediate pathological α-synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson's disease (PD). The aim of the present study was to explore soluble LAG-3 (sLAG-3) as a potential diagnostic biomarker for PD. METHODS: Serum sLAG-3 concentrations were measured by a quantitative ELISA for patients with PD, essential tremor (ET) and age- and sex-matched controls. The relationships between sLAG-3 and clinical phenotype were assessed via correlation analysis and logistic regression. RESULTS: Serum sLAG-3 levels in patients with PD were significantly higher than those in ET patients and age- and sex-matched controls. The area under the curve of serum sLAG-3 in differentiating PD from age- and sex-matched controls was 0.82. Serum sLAG-3 was associated with non-motor symptoms and excessive daytime sleep. CONCLUSION: sLAG-3 is a candidate novel biomarker for PD.
OBJECTIVE:Lymphocyte activation gene-3 (LAG-3) could mediate pathological α-synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson's disease (PD). The aim of the present study was to explore soluble LAG-3 (sLAG-3) as a potential diagnostic biomarker for PD. METHODS: Serum sLAG-3 concentrations were measured by a quantitative ELISA for patients with PD, essential tremor (ET) and age- and sex-matched controls. The relationships between sLAG-3 and clinical phenotype were assessed via correlation analysis and logistic regression. RESULTS: Serum sLAG-3 levels in patients with PD were significantly higher than those in ET patients and age- and sex-matched controls. The area under the curve of serum sLAG-3 in differentiating PD from age- and sex-matched controls was 0.82. Serum sLAG-3 was associated with non-motor symptoms and excessive daytime sleep. CONCLUSION: sLAG-3 is a candidate novel biomarker for PD.
Authors: Hung Li Wang; Chin Song Lu; Tu Hsueh Yeh; Yu Ming Shen; Yi Hsin Weng; Ying Zu Huang; Rou Shayn Chen; Yu Chuan Liu; Yi Chuan Cheng; Hsiu Chen Chang; Ying Ling Chen; Yu Jie Chen; Yan Wei Lin; Chia Chen Hsu; Huang Li Lin; Chi Han Chiu; Ching Chi Chiu Journal: J Clin Neurol Date: 2019-10 Impact factor: 3.077
Authors: Stephanie E A Burnell; Lorenzo Capitani; Bruce J MacLachlan; Georgina H Mason; Awen M Gallimore; Andrew Godkin Journal: Immunother Adv Date: 2021-12-20
Authors: Marc Emmenegger; Elena De Cecco; Marian Hruska-Plochan; Timo Eninger; Matthias M Schneider; Melanie Barth; Elena Tantardini; Pierre de Rossi; Mehtap Bacioglu; Rebekah G Langston; Alice Kaganovich; Nora Bengoa-Vergniory; Andrès Gonzalez-Guerra; Merve Avar; Daniel Heinzer; Regina Reimann; Lisa M Häsler; Therese W Herling; Naunehal S Matharu; Natalie Landeck; Kelvin Luk; Ronald Melki; Philipp J Kahle; Simone Hornemann; Tuomas P J Knowles; Mark R Cookson; Magdalini Polymenidou; Mathias Jucker; Adriano Aguzzi Journal: EMBO Mol Med Date: 2021-07-26 Impact factor: 12.137